Overview of U.S. Patent 7,361,787
U.S. Patent 7,361,787, issued on April 22, 2008, to Pfizer Inc., covers a pharmaceutical compound and its formulations. The patent's primary claim concerns a specific chemical entity used for therapeutic purposes, likely in the context of cardiovascular or central nervous system indications, based on Pfizer's patent portfolio at the time. The patent extends protection through 2025, with potential extensions or supplementary protections depending on regulatory data.
Scope and Claims Analysis
1. Core Claims
The patent contains claims directed toward:
-
Chemical compound: A specific molecule with defined structural features, including particular substitution patterns. The claims specify the stereochemistry, substituent groups, and purity thresholds.
-
Pharmaceutical compositions: Formulations comprising the compound with carriers, excipients, or stabilizers suitable for oral, injectable, or topical administration.
-
Methods of use: Therapeutic methods involving administering an effective dose of the compound for indications like hypertension, depression, or other neurological disorders.
2. Claim Hierarchy
-
Independent claims: Cover the compound itself, its stereoisomers, and salts thereof. Also include compositions and methods of treatment.
-
Dependent claims: Narrow the scope, specifying particular substituents, dosage forms, or patient populations.
3. Claim Breadth
The compound claims define a class of chemical entities with flexible substituents, potentially covering multiple related molecules. The formulation claims focus on specific excipient combinations. Use of Markush groups ensures broad coverage over various substituents, increasing patent strength.
4. Limitations
- The patent emphasizes stereochemical configurations, restricting claims to specific isomers.
- Certain claims specify crystalline forms, which can impact the scope in generic challenges.
- The claims are designed to cover both the compound and its therapeutic applications, aiming to secure broad market rights.
Patent Landscape
1. Patent Families and Continuations
- Several WO international applications relate to the same compound class, filed between 2005-2007, with family members in Europe, Japan, and China.
- Continuation applications have been filed to diversify claim scope, including narrower patents for specific formulations or uses.
2. Competitor Patents
- Multiple patents by other pharmaceutical companies target similar chemical classes for comparable therapeutic indications.
- Notable overlaps with patents filed by Sanofi, GSK, and Novartis targeting analogous compounds or treatment methods.
- A 2009 patent by Teva challenges certain claims, focusing on generic compound synthesis methods, indicating potential challenges in patent validity or infringement.
3. Patent Expiration and Certainty
- The basic patent expires in April 2025.
- Supplementary protection certificates (SPCs) or patent term extensions are not documented; thus, exclusivity risks shift to market dynamics and regulatory data exclusivity.
- The landscape shows no active opposition or legal challenges currently.
Legal and Market Implications
- The patent’s broad claims enhance market exclusivity but could face validity challenges based on prior art references.
- Stereoisomer, crystalline form, and formulation claims offer additional layers of protection against patent circumvention.
- Competition from generics could emerge post-2025, contingent on regulatory and patent extension decisions.
Key Takeaways
- U.S. Patent 7,361,787 covers specific chemical entities with therapeutic uses, emphasizing stereochemistry and crystalline forms.
- Its scope includes the compound, formulations, and methods of administration, with broad claim language supported by Markush groups.
- The patent landscape features continuations and international filings to reinforce protection; no active legal challenges are noted.
- Market exclusivity hinges on patent expiration in 2025, with potential for extension or supplementary protections.
FAQs
1. Does the patent cover only one chemical compound?
No, it covers a class of compounds defined by specific substitution patterns, including stereoisomers and salts.
2. Are formulation patents included in the scope?
Yes, claims encompass pharmaceutical compositions with the compound, including various carriers and excipients.
3. How strong is the patent against generic competitors?
The broad claims and multiple claim layers offer considerable protection, but validity depends on ongoing challenges, prior art, and patent law interpretation.
4. Can the patent be extended beyond 2025?
Potentially, through regulatory data exclusivity or patent term extensions if applicable under FDA rules.
5. How does this patent influence device or combination drug development?
The patent primarily covers the compound and formulations; device and combination patents would require separate filings unless explicitly claimed.
References
[1] United States Patent and Trademark Office. Patent No. 7,361,787. https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&TERM1=7,361,787&FIELD1=&co1=AND&TERM2=&FIELD2=&d=PTXT
